Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
Authors
Keywords
-
Journal
Vaccines
Volume 9, Issue 4, Pages 372
Publisher
MDPI AG
Online
2021-04-13
DOI
10.3390/vaccines9040372
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
- (2021) Danniel Zamora et al. BLOOD
- Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients
- (2020) Anthony Anderson et al. CLINICAL TRANSPLANTATION
- Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation
- (2020) Jiaqi Fang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation
- (2020) George L. Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation – A Single Centre Study
- (2020) URSINA STUDER et al. ANTICANCER RESEARCH
- Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients
- (2019) Lynn El Haddad et al. JOURNAL OF MEDICAL VIROLOGY
- Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience
- (2019) Andrew Lin et al. Transplant Infectious Disease
- Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
- (2019) Francisco M. Marty et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
- (2017) Francisco M. Marty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
- (2016) P. Teira et al. BLOOD
- Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.
- (2016) Per Ljungman et al. CLINICAL INFECTIOUS DISEASES
- Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
- (2016) Stavroula Masouridi-Levrat et al. Frontiers in Immunology
- Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
- (2016) Margaret L Green et al. Lancet Haematology
- Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients
- (2016) David Navarro et al. Open Forum Infectious Diseases
- The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation
- (2014) Per Ljungman CURRENT OPINION IN HEMATOLOGY
- Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs
- (2011) H. Nakamae et al. HAEMATOLOGICA
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
- (2009) Marcie Tomblyn et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now